Broader Nasdaq biotech trends remain constructive, enhancing the probability that CHRS stock price forecast estimates reach near-term targets. With a 22% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Coherus BioSciences. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders. Multiple analysts have issued price targets for $CHRS recently. We have seen 2 analysts offer price targets for $CHRS in the last 6 months, with a median target of $4.025. Based on recent market updates, CHRS stock price forecast points to a trading range between $1.80 and $2.20 for Q3 2024, influenced by pipeline advancements and FDA feedback timelines.